The global cystic fibrosis market size was estimated to be USD 12.31 billion in 2023 and is expected to reach at USD 136.64 billion by 2034 with a CAGR of 24.46% during the forecast period 2024-2034. Increase in the incidence of cystic fibrosis, growing awareness regarding the progressive genetic disorder, rising adoption of pharmaceutical treatments, extensive accessibility to various treatment options, surge in research & development investments by major players, growing technological advancements, a heightened emphasis on developing innovative gene therapy solutions, and increasing regulatory approval of novel products for the treatment of cystic fibrosis are some of the key factors boosting the market growth.
Increasing regulatory approval of novel products for the treatment of cystic fibrosis is predicted to boost the market growth during the forecast period. Cystic fibrosis (CF) is a genetic disorder resulting from mutations in specific genes that regulate the secretion of certain bodily fluids. These mutations impact various organs, causing an increased viscosity in mucous and sweat. The disorder disrupts the normal function of the electrolyte transport system, leading to the absorption of sodium and water by cells and resulting in issues related to sweat and mucous gland function. Consequently, individuals with this condition experience increased infection risks in both the upper and lower respiratory tracts, necessitating the development of innovative therapeutics. For instance, in September 2022, Vertex Pharmaceuticals Incorporated has disclosed that the U.S. Food and Drug Administration (FDA) has granted approval for the extended application of ORKAMBI (lumacaftor/ivacaftor) to encompass children with cystic fibrosis (CF) aged 12 to less than 24 months, possessing the homozygous F508del mutation (F/F genotype) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
By drug class, cystic fibrosis transmembrane conductance regulator (CFTR) modulators was the highest revenue-grossing segment in the global cystic fibrosis market in 2023 owing to the developing R&D efforts, expanding awareness of hereditary disorders that worsen over time, and increased use of medication treatments. Additionally, Bronchodilators is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of respiratory conditions including asthma and COPD, increasing use for individuals with obstructive lung problems and respiratory diseases, growing number of product approvals and launches. For instance, in March 2022, The U.S. Food and Drug Administration (FDA) has approved Mylan Pharmaceuticals Inc., a subsidiary of Viatris, for its Abbreviated New Drug Application (ANDA) for Breyna (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol). This information was disclosed by Viatris Inc. and Kindeva Drug Delivery L.P. This marks the initial approval of a generic version of AstraZeneca's Symbicort.
By route of administration, oral was the highest revenue-grossing segment in the global cystic fibrosis market in 2023 owing to the comfort and ease of taking the medications orally, as well as the rise of regulatory authority approvals. For instance, in October 2023, Bristol Myers Squibb has reported that the U.S. Food and Drug Administration (FDA) awarded Breakthrough Therapy Designation to BMS-986278. This potential first-of-its-kind, oral drug functions as a lysophosphatidic acid receptor 1 (LPA1) antagonist and is intended for the treatment of progressive pulmonary fibrosis (PPF), a severe and life-threatening condition. Additionally, parenteral is predicted to grow at the fastest CAGR during the forecast period owing to the expanding usage of non-invasive medical procedures including injections and inhalations, as well as a significant rise in the introduction of new pharmaceuticals.
By distribution channel, hospital was the highest revenue-grossing segment in the global cystic fibrosis market in 2023 owing to the growing number of patients visiting hospitals, expanding investment by key market participants, and growing demand for precise diagnosis and follow-up therapies under medical supervision. For instance, In January 2024, The Cystic Fibrosis Foundation has disclosed a fresh investment of up to $15 million for Prime Medicine to advance the development of its gene-editing technology, known as Prime Editing, specifically for cystic fibrosis (CF). Additionally, pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the increasing occurrence of the disease and a rise in collaboration amongst industry participants.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising regulatory approvals, a broad range of medicines readily available, expanding investment by significant players in the market, and an increase in the prevalence of cystic fibrosis. For instance, in December 2022, Vertex Pharmaceuticals Incorporated has reported that the Investigational New Drug (IND) application for VX-522 has received approval from the U.S. Food and Drug Administration. VX-522 is an mRNA therapy designed to address the root cause of cystic fibrosis (CF) lung disease in approximately 5,000 CF individuals who do not derive benefits from a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the an increase in the number of cystic fibrosis patients, rising healthcare costs, a rise in R&D efforts, and an increasing initiatives by market leaders. For instance, in March 2022, Vertex Pharmaceuticals Incorporated has revealed that TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is set to receive reimbursement through the Australian Pharmaceutical Benefits Scheme (PBS). This applies to the treatment of cystic fibrosis (CF) in individuals aged 12 years and older who possess at least one F508del mutation in the CFTR gene, which is the most prevalent mutation causing CF globally.
Increasing regulatory approval of novel products for the treatment of cystic fibrosis is predicted to boost the market growth during the forecast period. Cystic fibrosis (CF) is a genetic disorder resulting from mutations in specific genes that regulate the secretion of certain bodily fluids. These mutations impact various organs, causing an increased viscosity in mucous and sweat. The disorder disrupts the normal function of the electrolyte transport system, leading to the absorption of sodium and water by cells and resulting in issues related to sweat and mucous gland function. Consequently, individuals with this condition experience increased infection risks in both the upper and lower respiratory tracts, necessitating the development of innovative therapeutics. For instance, in September 2022, Vertex Pharmaceuticals Incorporated has disclosed that the U.S. Food and Drug Administration (FDA) has granted approval for the extended application of ORKAMBI (lumacaftor/ivacaftor) to encompass children with cystic fibrosis (CF) aged 12 to less than 24 months, possessing the homozygous F508del mutation (F/F genotype) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
By drug class, cystic fibrosis transmembrane conductance regulator (CFTR) modulators was the highest revenue-grossing segment in the global cystic fibrosis market in 2023 owing to the developing R&D efforts, expanding awareness of hereditary disorders that worsen over time, and increased use of medication treatments. Additionally, Bronchodilators is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of respiratory conditions including asthma and COPD, increasing use for individuals with obstructive lung problems and respiratory diseases, growing number of product approvals and launches. For instance, in March 2022, The U.S. Food and Drug Administration (FDA) has approved Mylan Pharmaceuticals Inc., a subsidiary of Viatris, for its Abbreviated New Drug Application (ANDA) for Breyna (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol). This information was disclosed by Viatris Inc. and Kindeva Drug Delivery L.P. This marks the initial approval of a generic version of AstraZeneca's Symbicort.
By route of administration, oral was the highest revenue-grossing segment in the global cystic fibrosis market in 2023 owing to the comfort and ease of taking the medications orally, as well as the rise of regulatory authority approvals. For instance, in October 2023, Bristol Myers Squibb has reported that the U.S. Food and Drug Administration (FDA) awarded Breakthrough Therapy Designation to BMS-986278. This potential first-of-its-kind, oral drug functions as a lysophosphatidic acid receptor 1 (LPA1) antagonist and is intended for the treatment of progressive pulmonary fibrosis (PPF), a severe and life-threatening condition. Additionally, parenteral is predicted to grow at the fastest CAGR during the forecast period owing to the expanding usage of non-invasive medical procedures including injections and inhalations, as well as a significant rise in the introduction of new pharmaceuticals.
By distribution channel, hospital was the highest revenue-grossing segment in the global cystic fibrosis market in 2023 owing to the growing number of patients visiting hospitals, expanding investment by key market participants, and growing demand for precise diagnosis and follow-up therapies under medical supervision. For instance, In January 2024, The Cystic Fibrosis Foundation has disclosed a fresh investment of up to $15 million for Prime Medicine to advance the development of its gene-editing technology, known as Prime Editing, specifically for cystic fibrosis (CF). Additionally, pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the increasing occurrence of the disease and a rise in collaboration amongst industry participants.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising regulatory approvals, a broad range of medicines readily available, expanding investment by significant players in the market, and an increase in the prevalence of cystic fibrosis. For instance, in December 2022, Vertex Pharmaceuticals Incorporated has reported that the Investigational New Drug (IND) application for VX-522 has received approval from the U.S. Food and Drug Administration. VX-522 is an mRNA therapy designed to address the root cause of cystic fibrosis (CF) lung disease in approximately 5,000 CF individuals who do not derive benefits from a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the an increase in the number of cystic fibrosis patients, rising healthcare costs, a rise in R&D efforts, and an increasing initiatives by market leaders. For instance, in March 2022, Vertex Pharmaceuticals Incorporated has revealed that TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is set to receive reimbursement through the Australian Pharmaceutical Benefits Scheme (PBS). This applies to the treatment of cystic fibrosis (CF) in individuals aged 12 years and older who possess at least one F508del mutation in the CFTR gene, which is the most prevalent mutation causing CF globally.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type, Material, Product, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Cystic Fibrosis Market Report 2023 - 2034
Cystic Fibrosis Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Mucolytics
- Bronchodilators
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
- Pancreatic Enzyme Supplements
- Others
Cystic Fibrosis Market Analysis & Forecast by Route Of Administration 2023 - 2034 (Revenue USD Bn)
- Parenteral
- Oral
Cystic Fibrosis Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Pharmacies
- Others
Cystic Fibrosis Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cystic Fibrosis Market: Drug Class Estimates & Trend Analysis
8. Cystic Fibrosis Market: Route Of Administration Estimates & Trend Analysis
9. Cystic Fibrosis Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Cystic Fibrosis Market
12. Europe Cystic Fibrosis Market
13. Asia Pacific Cystic Fibrosis Market
14. Latin America Cystic Fibrosis Market
15. MEA Cystic Fibrosis Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Mylan N.V.
- Genentech Inc.
- Gilead Sciences Inc.
- Novartis AG
- AbbVie Inc.
- Pfizer Inc.
- Vertex Pharmaceuticals Incorporated
- AstraZeneca
- Bayer AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 12.31 Billion |
| Forecasted Market Value ( USD | $ 136.64 Billion |
| Compound Annual Growth Rate | 24.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
